Use of inhibitors of bruton's tyrosine kinase (Btk)
AssigneePharmacyclics, Inc.
InventorsJoseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Claims31
A method for treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in an individual in need thereof, wherein the individual is treatment-naïve for CLL/SLL, comprising:
- administering to the individual once per day about 420 mg of an oral dose of a compound having the structure:
A method for treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in an individual in need thereof, wherein the individual is treatment-nave for CLL/SLL, comprising:
- administering to the individual once per day about 420 mg of an oral dose of a compound having the structure:
- wherein the individual has a 17p deletion.
Dependencies are inferred from the claim text.